Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 1,834 shares of the company's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total value of $190,515.92. Following the completion of the transaction, the insider now directly owns 14,913 shares in the company, valued at approximately $1,549,162.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Blueprint Medicines Trading Down 0.9 %
NASDAQ BPMC opened at $106.25 on Tuesday. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $110.93. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $6.50 billion, a PE ratio of -22.09 and a beta of 0.65. The firm's fifty day simple moving average is $91.77 and its 200-day simple moving average is $80.95.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts' consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The business had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. During the same period in the prior year, the business posted ($2.65) earnings per share. Blueprint Medicines's revenue for the quarter was up 85.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Blueprint Medicines Co. will post -5.38 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
get a piece of the profit from this land
From True Market Insiders | Ad
This isn’t the prettiest land on earth.
But it might be the most valuable.
And you don’t have to own, lease, or rent any land.
Click here to see my #1 investment for 2024.
BPMC has been the topic of several research reports. Barclays upped their price target on Blueprint Medicines from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday. Needham & Company LLC reaffirmed a "buy" rating and issued a $97.00 price target on shares of Blueprint Medicines in a report on Thursday, May 2nd. Piper Sandler upped their price target on Blueprint Medicines from $78.00 to $104.00 and gave the company a "neutral" rating in a report on Friday. The Goldman Sachs Group upped their price target on Blueprint Medicines from $121.00 to $168.00 and gave the company a "buy" rating in a report on Monday. Finally, StockNews.com raised Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $100.31.
Check Out Our Latest Stock Analysis on BPMC
Hedge Funds Weigh In On Blueprint Medicines
A number of hedge funds have recently modified their holdings of BPMC. Norges Bank acquired a new position in Blueprint Medicines during the fourth quarter worth $55,893,000. Polar Capital Holdings Plc increased its position in Blueprint Medicines by 108.0% during the third quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company's stock worth $52,229,000 after buying an additional 540,000 shares during the last quarter. Rock Springs Capital Management LP increased its position in Blueprint Medicines by 22.8% during the third quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company's stock worth $134,855,000 after buying an additional 498,622 shares during the last quarter. Avidity Partners Management LP increased its position in Blueprint Medicines by 81.1% during the third quarter. Avidity Partners Management LP now owns 751,600 shares of the biotechnology company's stock worth $37,745,000 after buying an additional 336,600 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Blueprint Medicines by 2,788.1% during the fourth quarter. Assenagon Asset Management S.A. now owns 269,658 shares of the biotechnology company's stock worth $24,873,000 after buying an additional 260,321 shares during the last quarter.
Blueprint Medicines Company Profile
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
